Search

Omeros Corp

Fechado

SetorSaúde

20.29 -1.98

Visão Geral

Variação de preço das ações

24h

Atual

Mín

20.41

Máximo

20.94

Indicadores-chave

By Trading Economics

Rendimento

-38M

13M

Vendas

19M

29M

P/E

Médio do Setor

11.206

55.725

EPS

0.02

Margem de lucro

46.381

Funcionários

175

EBITDA

-40M

18M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+30.64% upside

Dividendos

By Acuity

Próximos Ganhos

12 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

356M

1.3B

Abertura anterior

22.27

Fecho anterior

20.29

Sentimento de Notícias

By Acuity

22%

78%

27 / 339 Ranking em Healthcare

Omeros Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de set. de 2026, 20:02 UTC

News
Social Media

Omeros shares advance sharply after Cantor Fitzgerald upgraded the stock to Overweight, citing strong Yartemlea launch and reinstating a $22 price target.

21 de set. de 2026, 19:16 UTC

Omeros Corp has advanced during Monday's trading session, reaching a notable peak earlier in the day while remaining below its 20-day moving average.

18 de set. de 2026, 20:13 UTC

Omeros Corp's shares declined in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

17 de set. de 2026, 20:08 UTC

Omeros Corp is advancing sharply in Thursday's trading, having risen as much as 7% earlier before pulling back slightly, reflecting strong overall market gains.

16 de set. de 2026, 19:36 UTC

Omeros Corp is trading higher, having peaked earlier in the day, though it remains below its 20-day moving average amid a broader trend of lower closes.

15 de set. de 2026, 20:51 UTC

Omeros Corp shares are lower in after-market hours, continuing a five-session decline amid broader market pressures and elevated crude oil prices.

14 de set. de 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, continuing a trend of declines amid broader market pressure from rising crude oil prices.

10 de set. de 2026, 20:03 UTC

Omeros Corp shares are lower today, continuing a decline since Wednesday. Trading volume is notably high, reflecting increased investor activity.

3 de set. de 2026, 19:46 UTC

Omeros Corp shares are higher today, supported by a modest upward trend since Wednesday. Easing Treasury yields may contribute to positive market sentiment.

2 de set. de 2026, 23:01 UTC

Omeros Corp shares are lower in after-market hours, continuing a downward trend. No specific company news was identified to explain the movement.

1 de set. de 2026, 19:16 UTC

Omeros Corp shares are lower today, reflecting a decline since Monday's close amid rising global bond yields and inflationary pressures.

31 de ago. de 2026, 23:16 UTC

Omeros Corp shares are higher in after-market trading. No specific news was identified to explain this movement, which appears independent of broader market trends.

28 de ago. de 2026, 20:07 UTC

Omeros Corp shares are lower amid rising U.S. Treasury yields and inflation concerns. The stock peaked early but shifted to a downward trajectory.

27 de ago. de 2026, 22:01 UTC

Omeros Corp shares are lower in after-market trading, reflecting unusual volatility amid broader market concerns over the Federal Reserve's monetary policy and inflation pressures.

26 de ago. de 2026, 23:06 UTC

Omeros Corp shares are higher in after-market hours, with no specific news identified. The stock has gained significantly compared to last month's close.

25 de ago. de 2026, 23:12 UTC

Omeros Corp shares are lower in after-market hours following an unusual trading session, with no specific company news identified to explain the decline.

21 de ago. de 2026, 19:16 UTC

Omeros Corp shares are higher today, trading above their 20-day moving average, despite no specific news to explain the price action.

20 de ago. de 2026, 23:32 UTC

Omeros Corp shares are lower in after-market trading, reversing from a high of 0.70% to a low of -1.99%. No specific news was identified.

19 de ago. de 2026, 22:51 UTC

Omeros Corp shares are trading lower in after-market hours, reaching a session low without any specific news to explain the decline.

18 de ago. de 2026, 23:16 UTC

Omeros Corp. shares are lower in after-market trading, retracing from earlier gains. This decline coincides with mixed performance in Asian markets amid global economic uncertainties.

17 de ago. de 2026, 23:06 UTC

Omeros Corp shares are lower in after-market trading, reaching a low of -1.21% before partially recovering. The stock remains above its 20-day moving average.

15 de ago. de 2026, 00:01 UTC

Omeros Corp shares are higher in after-market trading, reflecting positive momentum as they trade above their 20-day moving average.

14 de ago. de 2026, 23:41 UTC

Omeros Corp shares are lower in after-market trading, reflecting broader market sentiment amid a surprise decline in U.S. retail sales for July.

13 de ago. de 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, following notable volatility without any specific company news to explain the decline.

12 de ago. de 2026, 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

11 de ago. de 2026, 23:41 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

10 de ago. de 2026, 23:51 UTC

Omeros Corp shares are lower in after-market hours, influenced by a recent labor report indicating job losses and reduced Fed rate hike expectations.

8 de ago. de 2026, 00:02 UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7 de ago. de 2026, 23:31 UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6 de ago. de 2026, 23:01 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

Comparação entre Pares

Variação de preço

Omeros Corp Previsão

Preço-alvo

By TipRanks

30.64% parte superior

Previsão para 12 meses

Média 27.5 USD  30.64%

Máximo 33 USD

Mínimo 22 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Omeros Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

27 / 339 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.